AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

FBIO · NASDAQ · Biotechnology

Fortress Biotech

Sources, funds and advances drug assets through a portfolio-company network.

$2.76

After-hours close−0.01 (−0.47%)

At close$2.77(−1.07%)

Something off on this page? Send us feedback.

Profile

Fortress Biotech, Inc.FBIOHealth Care

Sources, funds and advances biopharmaceutical assets through Fortress, controlled subsidiaries and partner companies. Monetization comes from product revenue and portfolio interests, including equity, dividends and royalties.

Sources, funds and advances biopharmaceutical assets through its own operations, controlled subsidiaries and partner companies. Product revenue and interests in portfolio companies, including equity, dividends and royalties, form the routes to monetization.

Works with academic, research and pharmaceutical institutions to identify and evaluate candidates, then provides funding and management services to development and commercializing companies. This approach connects direct drug development with a portfolio-company structure.

Recent outcomes include subsidiary Checkpoint's acquisition by Sun Pharma and Cyprium's sale of a Priority Review Voucher after FDA approval of ZYCUBO for pediatric Menkes disease. The model depends on portfolio companies progressing assets and on value being realized through product, ownership and royalty interests.

Company facts

CEOLindsay A. Rosenwald, M.D.

ListedApr 28, 2015

ExchangeNASDAQ

HeadquartersBay Harbor Islands, FL

CountryUnited States

Employees78

CIK0001429260

ISINUS34960Q3074

Key statistics

Market cap$92.0M

EPS (ttm)$2.65

P/E (ttm)1.04

ROE103.5%

P/B0.5344

P/S1.34

Dividend yield—

Beta1.04vs XLV −0.42

Year to date −31.3% · Average volume (30d) 642.9K

Analysts

Price target, next 12 months$5.00+80.5%Median of 6 analysts · vs the Aug 28 close

ConsensusBuy6 of 6 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $2.77

High$5.00+80.5%

Median$5.00+80.5%

Low$5.00+80.5%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
May 18, 2026	Industrial Alliance Securities	Target	$5

Earnings

EPS

Estimate−$0.27

ReportedDue Nov 16, 2026

Revenue

Estimate$21.6M

ReportedDue Nov 16, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 12, 2026Q2 FY26	−$0.20	−$0.08	+60.0%	$18.3M	$18.7M	+2.3%	+8.36%
May 14, 2026Q1 FY26	−$0.22	$2.82	+1,381.8%	$16.3M	$16.0M	−1.8%	+4.78%
Mar 31, 2026Q4 FY25	$0.42	−$0.21	−150.0%	$26.2M	$16.1M	−38.5%	−11.47%
Nov 14, 2025Q3 FY25	−$0.43	$0.11	+125.6%	$21.0M	$17.6M	−16.1%	−0.38%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$13.1M	$16.4M	$17.6M	$16.1M	$16.0M	$18.7M
Gross profit	$8.3M	$11.5M	$11.9M	$10.6M	$8.7M	$11.6M
Operating income	−$22.3M	−$36.5M	−$6.8M	−$4.8M	−$7.7M	−$10.0M
Net income	−$10.6M	$15.5M	$5.9M	−$3.9M	$110.4M	−$468.0K
Diluted EPS	−$0.48	$0.45	$0.11	−$0.20	$2.82	−$0.08
Gross margin	63.5%	69.9%	67.4%	66.2%	54.2%	62.0%
Operating margin	-169.9%	-222.2%	-38.6%	-29.8%	-48.3%	-53.5%

Fiscal years (4-quarter sums)FY21 $68.8M · FY22 $75.7M · FY23 $84.5M · FY24 $57.7M · FY25 $63.3M

Revenue by product · Q2 FY26

Qbrexza$5.1M · 60%

Accutane$3.4M · 40%

Balance sheet, Jun 30, 2026Cash & short-term investments $196.6M · Total debt $64.8M · Total assets $316.7M · Shareholders' equity $164.1M

Dividends

No dividends on record.

Ownership

Institutions 16.13%5.36M sharesInsiders 27.70%9.20M sharesOther 56.17%18.66M shares

Shares outstanding 33.22M · Float 23.09M · 69.5% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Lindsay A. Md Rosenwald · director, 10 percent owner, officer: PRESIDENT, CEO & CHAIRMAN	4.59M	13.81%	Form 4	Mar 20, 2026
Highbridge Capital Management, LLC	2.73M	9.00%	13G	Oct 25, 2024
Michael S. Weiss · director, officer: Executive Vice Chairman	2.28M	6.85%	Form 4	Mar 20, 2026
David Jin · officer: Chief Financial Officer	1.65M	4.97%	Form 4	Jun 24, 2026
Opaleye Management Inc.	1.04M	3.14%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.